Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 1218

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7A
Chunk 1218
---
 and Exchange Commission on September 21, 2007). 
  
    10.2#
     
    Imprimis
    Pharmaceuticals, Inc. Amended and Restated 2007 Stock Incentive and Awards Plan (incorporated herein by reference to Exhibit 10.3
    to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8,
    2013).

 70 

    10.3#
     
    Amendment
    No. 1 to Imprimis Pharmaceuticals, Inc. Amended and Restated 2007 Incentive Stock and Awards Plan (incorporated herein by reference
    to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission
    on November 6, 2013).
  
    10.4#
     
    Form
    of Incentive Stock Option Agreement (incorporated herein by reference to Exhibit 10.12 to the Current Report on Form 8-K of Imprimis
    Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007). 
  
    10.5#
     
    Form
    of Non-Qualified Stock Option Agreement (incorporated herein by reference to Exhibit 10.13 to the Current Report on Form 8-K of Imprimis
    Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007). 
  
    10.6#
     
    Form
    of Restricted Stock Unit Agreement (incorporated herein by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of Imprimis
    Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8, 2013).
  
    10.7#
     
    Employment
    Agreement, dated as of April 25, 2016, by and between Imprimis Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference
    to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 26,
    2016).
  
    10.8#
     
    Employment
    Agreement, dated as of April 25, 2016, by and between Imprimis Pharmaceuticals, Inc. and